Free Trial

Oppenheimer's Rating of Vanda Pharmaceuticals on 9/23/2026

On September 23, 2026, Oppenheimer updated its outlook on Vanda Pharmaceuticals (NASDAQ:VNDA) with the action "Initiated Coverage", setting a "Outperform" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Oppenheimer Holdings, Inc.

DateCompanyAction
10/14/2026
AAON, Inc. stock logo
AAON
AAON
Reiterated Rating
10/14/2026
DigitalOcean Holdings, Inc. stock logo
DOCN
DigitalOcean
Boost Price Target
10/14/2026
Veeco Instruments Inc. stock logo
VECO
Veeco Instruments
Reiterated Rating
10/14/2026
Veru Inc. stock logo
VERU
Veru
Reiterated Rating
10/14/2026
Workday, Inc. stock logo
WDAY
Workday
Reiterated Rating
10/14/2026
Lennox International, Inc. stock logo
LII
Lennox International
Lower Price Target
More Ratings From Oppenheimer Holdings, Inc.